175205-24-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
1-(2-(TRIFLUOROMETHOXY)PHENYL)-2-THIOUREA is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals due to its unique chemical structure and reactivity, contributing to the development of new drugs and pesticides.
Used in Research and Development:
In the field of research, 1-(2-(TRIFLUOROMETHOXY)PHENYL)-2-THIOUREA is utilized for its potential anti-cancer and anti-inflammatory properties, making it a subject of study for the development of novel therapeutic agents.
Used in Coordination Chemistry:
1-(2-(TRIFLUOROMETHOXY)PHENYL)-2-THIOUREA serves as a ligand in coordination chemistry, playing a crucial role in the formation of coordination compounds, which have applications in various areas such as catalysis, materials science, and medicinal chemistry.
Used in Organic Synthesis:
As a reagent in organic synthesis, 1-(2-(TRIFLUOROMETHOXY)PHENYL)-2-THIOUREA is employed to facilitate specific chemical reactions, contributing to the synthesis of complex organic molecules for a variety of applications.

Upstream product

• 175205-33-1 1-isothiocyanato-2-trifluoromethoxybenzene 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 1535-75-7 2-trifluoromethoxy aniline 
• 1147550-11-5 ammonium thiocyanate 

Downstream Products

• 235101-36-7 SKA-35 

Relevant academic research and scientific papers

IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.

METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.

Riluzole series. synthesis and in vivo 'antiglutamate' activity of 6- substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines

Two series of analogues of riluzole, a blocker of excitatory amino acid mediated neurotransmission, have been synthesized: monosubstituted 2- benzothiazolamines and 3-substituted derivatives. Of all the compounds prepared in the first series, only 2-benzothiazolamines bearing alkyl, polyfluoroalkyl, or polyfluoroalkoxy substituents in the 6-position showed potent anticonvulsant activity against administration of glutamic acid in rats. The most active compounds displaying in vivo 'antiglutamate' activity were the 6-OCF3 (riluzole), 6-OCF2CF3, 6-CF3, and 6-CF2CF3 substituted derivatives with ED50 values between 2.5 and 3.2 mg/kg i.p. Among the second series of variously substituted benzothiazolines, compounds as active as riluzole or up to 3 times more potent were identified in two series: benzothiazolines bearing a β-dialkylaminoethyl moiety and compounds with an alkylthioalkyl chain and their corresponding sulfoxides and sulfones. The most potent derivatives were 2-imino-3-(2-methylthio)- and 2-imino-3-(2- methylsulfinyl)-ethyl-6-trifluoromethoxybenzothiazolines (61 and 64, ED50 = 1.0 and 1.1 mg/kg i.p., respectively). In addition, intraperitoneal administration of some of the best benzothiazolines protected mice from mortality produced by hypobaric hypoxia.